Antibody therapy of lymphoma

Bibliography

• ARMITAGE JO: Treatment of non- Hodgkin's lymphoma. N Engl. I Med. (1993) 328:1023–1030.
   PubMed Web of Science ®Google Scholar
• HORNING SJ: Natural history of and therapy for the Indolent non Hodgkin's lymphomas. Semin. Oncol (1993) 20:75–88.
   PubMed Web of Science ®Google Scholar
• FOON KA, SHERWIN SA, ABRAMS PG et al.: Treatment of advanced non-Hodgkin's lymphoma with recombinant alpha-interferon. N Engl. I Med. (1984) 311:1148–1152.
   PubMed Web of Science ®Google Scholar
• KWAK LW, CAMPBELL MJ, CZERWINSKI DK et al: Induction of immune responses inpatients with B cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl. I Med. (1992) 327:1209–1215.
   PubMed Web of Science ®Google Scholar
• ILLIDGE TM, JOHNSON PWJ: Emerging role of RIT in the management of haematological malignancies. Br. Haematol (2000) 108(4):679–688.
   PubMed Web of Science ®Google Scholar
• •Recent comprehensive review of RIT for lymphomas and leukaemias.
   Google Scholar
• GROSSBARD ML, PRESS OW,APPELBAUM FR et al.: Monoclonal antibody-based therapies of leukaemia and lymphoma. Blood (1992) 80:863–878.
   Google Scholar
• •Overview of target antigen requirements for effective antibody-based therapy.
   Google Scholar
• DAVIS TA, MALONEY DG, CZERWINSKI DK et al.: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkins lymphoma. Blood (1998) 92:1184–1190.
   PubMed Web of Science ®Google Scholar
• PRESS OW, EARY JF, APPELBAUM FR et al.: Radiolabelled antibody therapy of B cell lymphoma with autologous bone marrow support. N Engl. I Med. (1993) 329:1219–1224.
   PubMed Web of Science ®Google Scholar
• HALE G, CARK MR, MARCUS R et al: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2:1394–1399.
   PubMed Web of Science ®Google Scholar
• MILLER RA, MALONEY DG, WARNKE R et al: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl. j Med. (1982) 306:517–522.
   PubMed Web of Science ®Google Scholar
• KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497. Landmark paper detailing technique for production of mAbs.
   Google Scholar
• SCHROFF RW, FOON KA, BEATTY SM et al.: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. (1985) 45:879–885.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al: IDEC-C2B8 anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90:2188–2195.
   PubMed Web of Science ®Google Scholar
• MALONEY DG,SMITH B, APPELBAUM FR: The anti-tumour effect of monoclonal anti CD20 antibody (mAlp) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood (1996) 88:637a (Suppl. 1). Abstract.
   Google Scholar
• SCHWANER I, VON ENGELHARDT V,JORDANOVA M et al: Rituximab induced complement cascade activation is related to adverse events and bone marrow involvement. Blood (2000) 96\(Suppl. 1):507a. Abstract 2181.
   Google Scholar
• TEDDER TF, ENGEL P: A regulator of cell cycle progression of B lymphocytes. Immunol Today (1994) 15:450–454.
   PubMedGoogle Scholar
• VAN DER KOLK LE, EVERS LM, VAN LIER RA et al.: Intracellular pathways of CD20-induced apoptosis. Blood (1999): 630-631a (Suppl. 1). Abstract.
   Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, BODKIN DJ et al: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. j Clin. Oncol (1997) 15(10):3266–3274.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK etal.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphomas: half of patients respond to a four-dose treatment program. J. Clin. Oncol (1998) 16:2825–2833.
   Google Scholar
• ••Pivotal Phase II trial of rituximab inindolent NHL
   Google Scholar
• MALONEY D: Monoclonal antibodies in lymphoid neoplasia: Principles for optimal combined therapy. Semin. Hematol (2000) 37\(Suppl. 7):17–26.
   Google Scholar
• •Comprehensive overview addressing critical issues in combining antibody-based therapy and chemotherapy.
   Google Scholar
• PIRO LD, WHITE CA, GRILLO-LOPEZ AJ etal.: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol (1999) 10:655–661.
   Google Scholar
• RAWSTRON AC, DAVIES FE, MORGAN GJ etal.: Monitoring of residual disease after Campath-1H therapy of refractory chronic lymphocytic leukemia. Blood (1998) 92 (Suppl. 1):105a. Abstract.
   Google Scholar
• RAI KR: New biologic therapies. Semil. Hematol (1999) 36:12–17.
   PubMedGoogle Scholar
• LINK BK, WANG H, BYRD JC etal.: Phase 1 trial of humanised anti 1D10 (HulD10) monoclonal antibodies targeting class II molecules in patients with relapsed lymphoma. Proc. Am. Soc. Clin. Oncol (2000) 19:24a.
   Google Scholar
• LEONARD JP, COLEMAN M, SCHUSTER MW et al.: Immunotherapy of NHL with epratuzumab (anti CD22 monoclonal antibody): Excellent tolerability with objective responses. Proc. Am. Soc. Oncol (2000) 19:17a. Abstract.
   Google Scholar
• JUWEID ME, STADTMAUER E, HADAR G et al: Pharmacokinetics, dosimetry, and initial therapeutic results with 1131 and Y90 labeled humanised LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. CMl. Cancer Res. (1999) 5(10 Suppl.):3292s–3303s.
   Google Scholar
• KAMINSKI MS, ZASADNY KR, FRANCIS IR et al: I-131 anti-Bl radioimmunotherapy for B cell lymphoma. j Clin. Oncol (1996) 14:1974–1981.
   PubMed Web of Science ®Google Scholar
• •Phase I/II dose escalation trial, which determined the current dosing schedule for non-myeloablative RIT using 1–131 anti-Bl.
   Google Scholar
• KAMINSKI MS, ZASADNY KR, FRANCIS IR et al.: Radioimmunotherapy of B-cell lymphoma with [Iodine 1311 anti-B1 (anti CD 20) antibody. N Engl. j Med. (1993) 329:459–465.
   PubMed Web of Science ®Google Scholar
• •Initial report of non-myeloablative RIT using 1–131 anti-Bl.
   Google Scholar
• VOSE J, SALEH M, LISTER A etal.: Iodine-131 anti-Bl antibody for non-Hodgkin's lymphoma (NHL): overall clinical trial experience. Proceedings of the American Society of Clinical Oncology (1998).
   Google Scholar
• KAMINSKI MS, ESTS J, KENNETH R et al.: Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: updated results and long term follow-up of the University of Michigan experience. Blood (2000) 98(4):1259–1265
   Google Scholar
• ••Long-term safety and survival data withfollow-up of up to 8 years after 131I tositumomab.
   Google Scholar
• KAMINSKI MS, ZELENETZ AD, PRESS 0 et al: Multi-centre, Phase III study of iodine-131 tositumomab (anti-Bl antibody) for chemotherapy refractory low grade or transformed low grade non-Hodgkin's lymphoma. Blood (1998) 92:316a. Abstract.
   Google Scholar
• HORNING SJ, LUCAS JB, YOUNES A et al.: Iodine-I 131 tositumomab for non-Hodgkin's lymphoma patients who progressed after treatment with rituximab: results of a multi-center Phase II study. Blood(2000) 96\(Suppl. 0:508. Abstract 2184.
   Google Scholar
• KAMINSKI MS, GRIBBIN T, ESTES J et al.: I-131 anti-Bl antibody for previously untreated follicular lymphoma: clinical and molecular remission. Proc. Am. Soc. Clin. Oncol (1998) 17:2a. Abstract.
   Google Scholar
• WITZIG TE, WHITE CA, WISEMAN GA et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD 20+ B-cell non-Hodgkin's lymphoma. I Clin. Oncol. (1999) 17:3793–3803.
   PubMed Web of Science ®Google Scholar
• WITZIG, TE, WHITE CA, GORDON LI et al.: Final results of a randomized controlled study of Zevalinrm radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL. Blood (2000) 96(11):831a.
   Web of Science ®Google Scholar
• PRESS OW, FARR AG, BERROZ KI et al.: Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. (1989) 49:4904–4912.
   Web of Science ®Google Scholar
• PRESS OW, SHAN D, HOWELL-CLARK J et al.: Comparative metabolism and retention of iodine-125, yttrium-90 and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. (1996) 56:2123–2129.
   PubMed Web of Science ®Google Scholar
• DE NARDO SJ, DE NARDO GL, MACEY DJ: Dose fractionated radioimmunotherapy of lymphoma with I-131 Lym-1. Br. J. Cancer (1989) 59:313.
   Web of Science ®Google Scholar
• DE NARDO GL, DENARDO SJ, GOLDSTEIN D S et al.: Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. I Clin. Oncol. (1998) 16:3246.
   Google Scholar
• LIU SY, EARY JF, PETERSDORF SH et al.: Follow-up of relapsed B cell lymphoma patients treated with iodine-131-labeled anti-CD 20 antibody and autologous stem cell rescue. I Clin. Oncol (1998) 16:3270–3278.
   PubMed Web of Science ®Google Scholar
• •Long-term data of most impressive results ever achieved using myeloablative doses of RIT.
   Google Scholar
• GROSSBARD ML, FREEDMAN AS, RITZ J et al.: Serotherapy of B-cell neoplasms with anti-B4 blocked ricin: A Phase 1 trial of daily bolus infusion. Blood (1992) 80:576–578.
   Google Scholar
• DAVIS TA, GRILLO-LOPEZ AJ, WHITE CA et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. j Clin. Oncol. (2000) 18(17):3135–3143.
   PubMed Web of Science ®Google Scholar
• •First report on re-treatment with rituximab demonstrating similar efficacy and safety to initial therapy.
   Google Scholar
• DEMIDEM, LAM T, ALAS S et al.: Chimeric anti CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharmaceut. (1997) 12:177–186.
   PubMed Web of Science ®Google Scholar
• CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. I Clin. Oncol. (1999) 17:268–276.
   Google Scholar
• •Initial reports of Phase II study of rituximab in combination with conventional chemotherapy.
   Google Scholar
• CZUCZMAN MS, JONAS C, STEPHAN M et al.: Pilot study of Rituxan in combination with fludarabine chemotherapy in patients with low grade or follicular non-Hodgkin's lymphoma. Proc. Am. Soc. Clin. Oncol. (1999) 18: Abstract 61.
   Google Scholar
• COIFFIER B, LEPAGE E, HERBRECHTR et al.: Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma: interim results of a randomised GELA trial. 421d Annual illeeting of ASH (2000). Abstract 950.
   Google Scholar
• ••Encouraging preliminary data suggestingthat addition of rituximab to CHOP improves survival in aggressive lymphoma.
   Google Scholar
• BUCKSTEIN R, IMRIE K, SPANER D et al.: Stem cell function and engraftment is not affected by in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. &main. Oncol. (1999) 26\(Suppl. 4):115–122.
   Google Scholar
• BUCKSTEIN R, IMRIE K, SPANER D et al: Stem cell function and engraftment is not affected by in vivo purging' with rituximab for autologous stem cell treatment for patients with low grade non-Hodgkin's lymphoma. &wain. Oncol. (1999) 26:115-122\(Suppl. 14).
   Google Scholar